Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Mar 24, 2021 4:52pm
89 Views
Post# 32869037

RE:RE:RE:Final lines from the Canaccord report on today's news

RE:RE:RE:Final lines from the Canaccord report on today's newsThis is the company's job it would be useful if others WHO believe there are shortcomings in how they conduct their operations to send emails or call Leah. The company apparently is not happy with the valuation or how they have been treated by the journalists from where I come from if one isn't happy with how they have been treated they do something about it.


realitycheck4u wrote: Just email Ed Nash who writes the reports himself at enash@cgf.com  Someone here can gather up all the evidence and present it to him. The guy may actually come around.

scarlet1967 wrote: Let's call it final nail on the coffin, the company shouldn't let him come up with this garbage, they are officially a phase 1 oncology company so this idiot wants positive results before ascribing any value I can imagine when the company starts the phase 3 we will have more of this nonsense.
Correct the analysts or bypass them go directly after investors.




<< Previous
Bullboard Posts
Next >>